Arcutis Biotherapeutics, Inc. (ARQT) Historical Metrics

Arcutis Biotherapeutics, Inc. also develops ZORYVE foam seborrheic dermatitis, and scalp and body. Review ARQT fundamentals, ratios, and historical filing metrics on Finoriq.

Company Snapshot

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Company: Arcutis Biotherapeutics, Inc. (ARQT)
Ticker: ARQT
Market Cap: $3.5B
Latest Price: $27.76
Industry: Biotech & Pharma

Open insider transactions

Arcutis Biotherapeutics, Inc. (ARQT) Current Valuation Metrics

Static valuation preview for Arcutis Biotherapeutics, Inc. (ARQT). Market data retrieved 2026-07-08. Filing currency USD.

Metric	Value	Source
P/SMarket cap divided by latest TTM revenue.	8.56x	Revenue \| TTM Q1 2026
P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow.	132x	Operating Cash Flow \| TTM Q1 2026
Earnings YieldLatest TTM net income divided by market cap.	-0.07%	Net Income \| TTM Q1 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.	0.76%	Operating Cash Flow \| TTM Q1 2026
Price / BookMarket cap divided by stockholders' equity.	18.8x	Stockholders' Equity \| Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.